NCT05171244Recruiting
Use of Immersive Virtual Reality to Train the Multisensory Processing Capacities of Children Aged 8 to 16 Years-old With an Autism Spectrum Disorder: Single-center Randomized Pilot Study in Parallel Groups - SEVIRE. (Sensory Virtual Reality)
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
Autism Spectrum Disorder (ASD) is defined as a neurodevelopmental disorder that affects the functioning and development of social communication (DSM5 - 2013). ASD causes particularities in sensory treatments (auditory, visual), qualified as uni-modal. Added to this, there is difficulties to deal with prevailing stimuli of the environment (pluri-modal) ; parents report the discomfort of their child in this situation with "noisy" behavioral manifestations. Therapeutic social skills programs most often address the subject's lack of adjustment to their environment through understanding social rules and codes and cognitive treatment of situations. Thus, in order to relieve the sensory modulation disorders which can be the cause of social adjustment difficulties, it's propose to exercise the sensory habituation of children with ASD thanks to virtual reality scenarios restored in 3D immersion booth (the CAVE). The child will be exposed to multimodal stimulation during immersion sessions reproducing the conditions of an ecological environment. A therapist will accompany the child in the CAVE throughout the session. The investigators hypothesize that regular and repeated exposure to a simulated environment in the CAVE can improve multisensory treatment capacities and have a beneficial effect on the autonomy of children and adolescents with ASD in everyday situations.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 18 Nov 2021
- Start date
- 3 Mar 2022
- Primary completion date
- Oct 2027
- Lead sponsor
- University Hospital, Tours
- Diseases
- Autism
- NCT number
- NCT05171244
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 3 Mar 2022 to the primary completion date, Oct 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with methylphenidate. - Rare genetic syndrome.
Other illness
- Neuromotor disorders.
- Uncorrected visual disorders.
- Hearing impairment.
- Known epilepsy.
- Anxiety syndromes identified.
Other
- Hyper ADD / H type activity.
Who the study is looking for
- Child / adolescent aged 8 to 16 years, diagnosed with ASD (DSM-5, ADOS, ADI-R criteria).
- Without intellectual delay (QNV\> 70, WISC-IV or V, WAIS-III or IV).
- Benefiting from a treatment program at the University Center for Child Psychiatry (CHRU Bretonneau-Tours).
- Schooled in the ordinary school context (primary school, middle school, high school, ULIS).
- Having expressed their agreement to participate in the study.
- Whose parents or legal representatives have signed written consent.
- Whose parents or legal representatives are affiliated or beneficiaries of a social security scheme.
Age in the registry: 8 years to 16 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Le Centre universitaire de pédopsychiatrie Coordinator of this site? Confirm its status | Tours | France | Recruiting |
| Pedopsychiatry, University Hospital, Tours Coordinator of this site? Confirm its status | Tours | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.